HC Wainwright Begins Coverage on Dynavax Technologies (NASDAQ:DVAX)

Research analysts at HC Wainwright assumed coverage on shares of Dynavax Technologies (NASDAQ:DVAX) in a research note issued to investors on Wednesday, TipRanks reports. The brokerage set a “buy” rating and a $23.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 60.17% from the stock’s current price.

Several other analysts also recently issued reports on DVAX. The Goldman Sachs Group assumed coverage on Dynavax Technologies in a report on Friday, August 6th. They issued a “buy” rating and a $19.00 price target on the stock. TheStreet raised Dynavax Technologies from a “d-” rating to a “c-” rating in a report on Wednesday, August 18th. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies presently has a consensus rating of “Buy” and a consensus target price of $18.00.

NASDAQ:DVAX traded up $0.44 during trading hours on Wednesday, reaching $14.36. 64,405 shares of the stock were exchanged, compared to its average volume of 4,219,667. The company has a quick ratio of 2.43, a current ratio of 2.85 and a debt-to-equity ratio of 2.64. The firm has a 50 day simple moving average of $12.61 and a 200-day simple moving average of $10.42. Dynavax Technologies has a 52 week low of $3.58 and a 52 week high of $20.40. The stock has a market capitalization of $1.65 billion, a P/E ratio of -55.15 and a beta of 1.37.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Wednesday, August 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.06. Dynavax Technologies had a negative return on equity of 7.33% and a negative net margin of 3.37%. The company had revenue of $52.77 million for the quarter, compared to the consensus estimate of $44.04 million. As a group, analysts expect that Dynavax Technologies will post 0.65 earnings per share for the current year.

In other news, SVP Robert Janssen sold 80,000 shares of Dynavax Technologies stock in a transaction on Friday, August 6th. The stock was sold at an average price of $10.75, for a total transaction of $860,000.00. Following the transaction, the senior vice president now directly owns 6,861 shares in the company, valued at approximately $73,755.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Andrew A. F. Hack sold 2,000,000 shares of Dynavax Technologies stock in a transaction on Friday, August 27th. The shares were sold at an average price of $16.22, for a total value of $32,440,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 4,408,268 shares of company stock worth $58,580,545. 11.77% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of the company. Advisory Services Network LLC acquired a new stake in Dynavax Technologies during the second quarter valued at $31,000. Meeder Asset Management Inc. boosted its position in Dynavax Technologies by 6,339.7% during the second quarter. Meeder Asset Management Inc. now owns 4,379 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 4,311 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Dynavax Technologies during the second quarter valued at $50,000. Great West Life Assurance Co. Can boosted its position in Dynavax Technologies by 76.1% during the second quarter. Great West Life Assurance Co. Can now owns 7,414 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 3,204 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC boosted its position in Dynavax Technologies by 1,208.6% during the second quarter. O Shaughnessy Asset Management LLC now owns 7,747 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 7,155 shares during the last quarter. 78.27% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

Read More: Bollinger Bands

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.